IP Library Granted Patent US 11,141,438
Granted Patent B2
US 11,141,438 · App. 17/233,299 · Granted Oct 12, 2021

Restimulation of cryopreserved tumor infiltrating lymphocytes

Inventors: Ian Frank (Tampa, FL); Michael T. Lotze (Pittsburgh, PA)
Assignee: Iovance Biotherapeutics, Inc.
A61K35/17A01N1/0284A61P35/00C07K14/7051C07K16/00C12N5/0636C12N15/85G01N33/5005C07K2317/24C07K2319/03C07K2319/33C12N2501/04C12N2501/2302C12N2502/11C12N2502/1121C12N2502/99
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,141,438
App. No.
17/233,299
Granted
Oct 12, 2021
Kind
B2
Abstract

The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.

Claims (24)

1. A population of expanded tumor infiltrating lymphocytes (TILs), wherein the population of expanded TILs is a third population of TILs obtainable by a method comprising:

(a) performing a first expansion by (i) thawing a cryopreserved tumor digest comprising a first population of TILs from a tumor that was resected from a subject, digested after the resection, and cryopreserved after the digestion, and (ii) culturing the first population of TILs in a cell culture medium comprising IL-2 to produce a second population of TILs;

(b) performing a second expansion by supplementing the cell culture medium of the second population of TILs with additional IL-2, OKT-3, and antigen presenting cells (APCs), to produce a third population of TILs, and wherein the second expansion is performed for about 7 to 14 days in order to obtain the third population of TILs; and

(c) harvesting the third population of TILs obtained from step (b).

2. The population of expanded TILs according to claim 1 , wherein the method further comprises a step (d) of transferring the harvested third population of TILs from step (c) into an infusion bag.

3. The population of expanded TILs according to claim 2 , wherein the method further comprises a step (e) of cryopreserving the infusion bag comprising the harvested TIL population from step (d) using a cryopreservation process.

4. The population of expanded TILs according to claim 1 , wherein the tumor digest in step (a) was prepared by incubating a sample of the tumor that was resected from the subject in an enzymatic media.

5. The population of expanded TILs according to claim 4 , wherein the method further comprises disrupting the tumor sample mechanically so as to dissociate the tumor sample.

6. The population of expanded TILs according to claim 5 , wherein the method further comprises purifying the disassociated tumor sample using a density gradient separation.

7. The population of expanded TILs according to claim 4 wherein the enzymatic media comprises DNase.

8. The population of expanded TILs according to claim 7 , wherein the enzymatic media comprises 30 units/mL of DNase.

9. The population of expanded TILs according to claim 4 , wherein the enzymatic media comprises collagenase.

10. The population of expanded TILs according to claim 9 , wherein the enzymatic media comprises 1.0 mg/mL of collagenase.

11. The population of expanded TILs according to claim 1 , wherein the cell culture medium is CTS Optimizer.

12. The population of expanded TILs according to claim 1 , wherein the third population of TILs harvested in step (c) comprises sufficient TILs for use in administering a therapeutically effective dosage to a subject.

13. The population of expanded TILs according to claim 12 , wherein the therapeutically effective dosage of TILs comprises from about 1×10 9 to about 9×10 10 TILs.

14. The population of expanded TILs according to claim 1 , wherein the APCs comprise peripheral blood mononuclear cells (PBMCs).

15. The population of expanded TILs according to claim 1 , wherein the first expansion is performed within from about 3 to 11 days.

16. The population of expanded TILs according to claim 1 , wherein steps (a) through (c) are performed within about 24 days.

17. The population of expanded TILs according to claim 1 , wherein step (a) further comprises adding the thawed tumor digest into a closed system prior to culturing the first population of TILs.

18. The population of expanded TILs according to claim 17 , wherein the transition from step (a) to step (b) or the transition from step (b) to step (c) occurs without opening the system.

19. The population of expanded TILs according to claim 17 , wherein the transition from step (a) to step (b) occurs without opening the system.

20. The population of expanded TILs according to claim 17 , wherein the transition from step (b) to step (c) occurs without opening the system.

21. The population of expanded TILs according to claim 1 , wherein step (a) further comprises adding the thawed tumor digest into a closed system prior to culturing the first population of TILs, wherein the transition from step (a) to step (b) occurs without opening the system, and wherein the transition from step (b) to step (c) occurs without opening the system.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2022
From: FRANK, IAN; LOTZE, MICHAEL T.
To: LION BIOTECHNOLOGIES, INC.
Reel/Frame 061567/0271 →
CHANGE OF NAME Recorded Oct 27, 2022
From: LION BIOTECHNOLOGIES, INC.
To: IOVANCE BIOTHERAPEUTICS, INC.
Reel/Frame 061793/0296 →
Continuity (5)
Continuation 15751440
Provisional Application 62415452 · Oct 31, 2016
Provisional Application 62413387 · Oct 26, 2016
Provisional Application 62413283 · Oct 26, 2016
Related Publication 20210252063A1 · Aug 19, 2021